# (Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer

> **NCT02627703** · — · UNKNOWN · sponsor: **British Columbia Cancer Agency** · enrollment: 80 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** Oncotype DX

## Key facts

- **NCT ID:** NCT02627703
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-05
- **Primary completion:** 2017-12
- **Final completion:** —
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2016-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02627703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02627703, "(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02627703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*